Goodbye Saphris

Anonymous

Guest
Mr. Saunders said the company plans to use the $600 million remaining after stock repurchases to buy more drugs to fill out the company's offerings in gastrointestinal disorders, cardiovascular disease and hospital infections. "It would give us a full portfolio of products," Mr. Saunders said.

He said that the company plans to buy the U.S. rights to the Saphris schizophrenia treatment from Merck & Co. for $240 million upfront, plus additional payments if the drug meets certain sales targets.
 

<



Mr. Saunders said the company plans to use the $600 million remaining after stock repurchases to buy more drugs to fill out the company's offerings in gastrointestinal disorders, cardiovascular disease and hospital infections. "It would give us a full portfolio of products," Mr. Saunders said.

He said that the company plans to buy the U.S. rights to the Saphris schizophrenia treatment from Merck & Co. for $240 million upfront, plus additional payments if the drug meets certain sales targets.

Your point being....?...Aha... I get it... the disease areas don't match

Its Pharma strategy - don't ya know -- just buy anything and throw it together "PharmaBazaar" style
 




Your point being....?...Aha... I get it... the disease areas don't match

Its Pharma strategy - don't ya know -- just buy anything and throw it together "PharmaBazaar" style

Fuck safrus and Riodd too. Way things are goin reps will end up sellin dr. Scholls n coppertone. Wait, Merck will want you to be a Dr to sell those scholls. Fuckin tards. Dont worry cause diabetes n oncology will save mother. Hahaaaahhhhaaaaaaaa. F youuuuuuuuuuuuuu
 
















Similar threads

Replies
1
Views
2K
Merck
anonymous
Replies
18
Views
5K
Merck
anonymous
Replies
4
Views
2K
Merck
Anonymous
Replies
9
Views
2K
Merck
Anonymous